Collaboration between UK Biobank, GSK and Regeneron results in “largest open access resource of exome data”
A collaboration between UK Biobank, GSK and Regeneron has reportedly led to the creation of the “largest open access resource of exome sequence data linked to health records”.
This project has lead to new genetic data becoming available from the sequencing part of a genome from 50,000 participants.
According to Aris Baras, General Manager and Senior Vice President Regeneron Pharmaceuticals/Regeneron Genetics Center:
“We believe this is the largest open access resource of exome sequence data linked to robust health records in the world – and this is just the beginning
“There is so much actionable information in this resource that can be utilized by scientific minds around the globe. We are hard at work mining the data for novel findings that will accelerate science, innovative new medicines and improved patient care, and we are excited to have others join us in this important quest.”
Professor Fiona Watt, Executive Chair of UK Medical Research (which co-funds UK Biobank), added:
“UK Biobank was established to do science in new ways, and it is very pleasing to see industry and academia tackling health research together,” said Professor Fiona Watt, Executive Chair of the UK Medical Research, which has funded UK Biobank since its inception and continues to support enhancement activities. “Industry has led the way on this exome sequencing project, and the fruits of that work mean UK Biobank can now deliver important genetic data that would otherwise not be available to researchers.”
Read more on the announcement here.